Form 4: Apogee Therapeutics' Chief Medical Officer Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on November 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), sold shares of the company's common stock on November 6, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on September 27, 2023.
- A total of 5,326 shares were sold at a weighted average price of $58.91, with individual prices ranging from $58.50 to $59.23.
- An additional 1,339 shares were sold at a weighted average price of $59.96, with individual prices ranging from $59.55 to $60.05.
- Following these transactions, Dambkowski directly owns 267,463 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity under a pre-arranged plan.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2023-09-27 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-11-06 | Date of stock sale transactions. |
| 2024-11-08 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.